Rocket Pharmaceuticals lands $150M credit facility from Hercules Capital
What's the deal? Rocket Pharmaceuticals has entered a credit facility agreement with Hercules CapitalDealroom has a profile for this one. Try Dealroom → for up to $150 million. The debt financing will support Rocket's pivotal Phase 2 study of RP-A501 for Danon disease and its broader cardiovascular pipeline.
How it works: Rocket received $35 million at closing and may draw a further $35 million at its option. Another $30 million unlocks upon a specified Danon clinical milestone, and a final $50 million is subject to Hercules' investment committee approval.
The facility carries an initial 30-month interest-only period and a 48-month maturity, with extensions tied to milestones. It also includes warrants to purchase Rocket's common stock.
Why now? Rocket held $283.7 million in cash, equivalents, and investments as of June 30, 2026. With the initial $35 million, it expects to fund operations into the third quarter of 2028; additional borrowings could extend the runway into 2029.
What's the endgame? Rocket is a commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases, with a focus on inherited cardiovascular disorders. Its cardiovascular portfolio includes three clinical-stage gene therapy programs targeting hypertrophic, arrhythmogenic, and dilated cardiomyopathies.
"Building on the sale of our priority review voucher, this financing diversifies our sources of capital and strengthens our ability to execute and deliver on our cardiovascular strategy," said Gaurav Shah, chief executive officer of Rocket Pharmaceuticals.
Hercules framed the deal around Rocket's lead program. "We are pleased to provide a flexible financing solution that supports the Company's development priorities," said R. Bryan Jadot, senior managing director and group head of life sciences at Hercules Capital.
LifeSci CapitalDealroom has a profile for this one. Try Dealroom → served as financial advisor on the term loan, with PJTDealroom has a profile for this one. Try Dealroom → as capital markets advisor.
The signal: At $150 million, the facility ranks among the largest debt rounds for US health companies, in roughly the 97th percentile of more than 4,500 comparable deals. The staged structure reflects how capital-hungry gene therapy developers are turning to milestone-linked debt to stretch runway without diluting shareholders further.
Read more: business.thepilotnews.com
Image credit: Generated with Gemini
